-- Earnings Flash (FBIO) FORTRESS BIOTECH Reports Q1 Revenue $23.9M, vs. Street Est of $20.7M
4:04PM ET 5/12/2022 MT Newswires...
...
...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Fortress Biotech (FBIO) on Thursday said that it has commenced a phase 2 trial to evaluate the safety, efficacy, and immunogenicity of Triplex in eliciting...
...
Journey Medical Corp., a subsidiary of Fortress Biotech (FBIO), on Friday priced its initial public offering of about 3.52 million common shares at $10...
Journey Medical Corporation, a unit of Fortress Biotech (FBIO), said Monday it has commenced an initial public offering of 3.2 million shares at $10 to $12...
Fortress Biotech (FBIO) said Wednesday CUTX-101 met both primary and secondary efficacy endpoints in two pivotal studies in patients with Menkes disease, a...
Cyprium Therapeutics, a partner company of Fortress Biotech (FBIO), said Friday that with support from licensing partner Sentynl Therapeutics it obtained...